Global Health Investment Fund
Our namesake $108 million social impact investment fund, the Global Health Investment Fund (GHIF), has invested in companies developing interventions such as diagnostics, devices, vaccines and therapeutics that target diseases that disproportionately burden people living in low- and middle-income countries. GHIF’s portfolio companies have registered 13 products that have reached over 100 million people, improving global health and saving lives.
GHIF's financial performance has demonstrated that it is possible to generate meaningful financial returns by investing public, philanthropic, and private capital in global health product development.
The Global Health Investment Fund focuses on a wide range of infectious diseases and maternal/infant health conditions, including HIV/AIDS, malaria, tuberculosis, cholera, chikungunya, river blindness, and pre-eclampsia. Increasing access to existing products and interventions is also part of GHIF's mission. Most recently, several of the GHIF companies launched successful COVID-19 programs.
The innovative investment model pioneered by GHIC through its Global Health Investment Fund has also stimulated the launch of additional investment funds seeking to build upon this model and further magnify its impact.
GHIF Portfolio Investments
Targets: Malaria, G6PDd, HIV, dengue, HPV, Zika
Impact Objectives: Reduced cost of high-quality malaria RDTs; new, low-cost diagnostics for other diseases
Targets: Postpartum hemorrhage
Impact Objectives: Develop new gold-standard intervention for PPH
Targets: HIV, Ebola, HCV, malaria
Impact Objectives: Improved professional testing and self-testing
Targets: Preeclampsia (PE), gestational diabetes mellitus (GDM)
Impact Objectives: Early, affordable, point-of-care PE/GDM testing; ↓ maternal/infant mortality/morbidity
Impact Objectives: Increase global supply of affordable vaccine doses; deliver improved presentation at $1/dose
Targets: Tuberculosis (TB), HCV
Impact Objectives: Diagnosis of TB and HCV on a near-point-of-care molecular diagnostic platform, enabling more effective treatment
Intervention: Surgical device
Targets: Cataract-induced blindness and visual impairment
Impact Objectives: Expand access to vision-restoring cataract surgery in resource-limited settings
Targets: Onchocerciasis (river blindness)
Impact Objectives: Accelerate the eradication of onchocerciasis; improve treatment outcomes
Targets: Hookworm, Roundworm, Whipworm
Impact Objectives: Cure hundreds of millions of school-aged children from parasitic worm infections; expand the arsenal of anthelmintics
Intervention: Vaccines and therapeutics
Targets: Anti-venom for snakebites, vaccines for tuberculosis and pertussis
Impact Objectives: High-quality anti-venoms, increased access to Tdap vaccines in pregnancy, more effective protection against tuberculosis
Intervention: Vaccine platform
Targets: Chikungunya, Zika
Impact Objectives: Protect at-risk communities from public health challenges such as mosquito-transmitted viruses
Intervention: Biologics manufacturing technology platform
Targets: Polio, Measles, Rubella
Impact Objectives: Dramatic reductions in the cost of essential biologics; distributed manufacturing
"The private sector has all the tools to do the job. What is required is an innovative spirit, and a willingness to be as bold in the social arena as corporations are in the marketplace." – Jamie Dimon, Chairman and CEO, JP Morgan Chase & Co.